Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

@inproceedings{Loskog2016ImmunostimulatoryAG,
  title={Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients},
  author={Angelica Loskog and Aglaia Maleka and Sara M Mangsbo and Emma Svensson and Christina Lundberg and A. J. E. Nilsson and Johan Krause and Margr{\'e}t Agnarsd{\'o}ttir and Anders Sundin and H{\aa}kan Ahlstr{\"o}m and Thomas H. T{\"o}tterman and G Ullenhag},
  booktitle={British Journal of Cancer},
  year={2016}
}
Background:Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulatory gene therapy was evaluated in patients with MM.Methods… CONTINUE READING